Amsterdam, December 13, 2016 – Teva Europe BV has announced the appointment of Richard Daniell to the position of President & CEO of Teva Generics Europe, succeeding Dipankar Bhattacharjee who has been promoted to be President and CEO, Global Generic Medicines.
As General Manager of Teva UK Limited,
Richard Daniell commented on his appointment: “I’m deeply
With its European headquarters in Amsterdam, the Netherlands, Teva is Europe’s largest generic medicines producer, leveraging its portfolio of more than 1,800 molecules to produce a wide range of generic products in nearly every therapeutic area to help patients in nearly forty countries across the region. In specialtymedicines Teva has a world-leading position in innovative treatments for disorders of the central nervous system, including pain, as well as a strong portfolio of respiratory products. Teva uses its generics and specialtycapabilities to create new ways of addressing unmet patient needs by combining drug development capabilities with devices, services and technologies. Teva's net revenues in Europe in 2015 were €4.9 billion. For more information, visit www.tevapharm.com.